UB Paderborn / Katalog / Suche / in CDI

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2516-2522

2009

Volltextzugriff (PDF)

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2822-2830

2005

Volltextzugriff (PDF)

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Journal of clinical oncology, 2004-01, Vol.22 (1), p.157-165

2004

Volltextzugriff (PDF)

A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6233-6239

2005

Volltextzugriff (PDF)

Improvement in Oncology Practice Performance Through Voluntary Participation in the Quality Oncology Practice Initiative

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1893-1898

2008

Volltextzugriff (PDF)

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Clinical cancer research, 2014-12, Vol.20 (24), p.6295-6303

2014

Volltextzugriff (PDF)

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Cancer, 2005-10, Vol.104 (7), p.1548-1555

2005

Volltextzugriff (PDF)

Measuring Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice Initiative

Journal of clinical oncology, 2008-08, Vol.26 (23), p.3832-3837

2008

Volltextzugriff (PDF)

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

Clinical cancer research, 2010-04, Vol.16 (8), p.2450-2457

2010

Volltextzugriff (PDF)

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

Cancer, 2004-01, Vol.100 (1), p.36-43

2004

Volltextzugriff (PDF)

Development and future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative

Journal of clinical oncology, 2014-12, Vol.32 (35), p.3907-3913

2014

Volltextzugriff (PDF)

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

Cancer biology & therapy, 2013-07, Vol.14 (7), p.557-563

2013

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

Journal of thoracic oncology, 2009-11, Vol.4 (11), p.1397-1403

2009

Volltextzugriff (PDF)

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

Journal of clinical oncology, 2000-06, Vol.18 (11), p.2234-2244

2000

Volltextzugriff (PDF)

Evolution and elements of the quality oncology practice initiative measure set

Cancer control, 2009-10, Vol.16 (4), p.312-317

2009

Volltextzugriff (PDF)

Caring for patients at the end of life

Annals of internal medicine, 2002-03, Vol.136 (6), p.1 paragraph

Eisenberg, Peter D

2002

Volltextzugriff (PDF)

A revisitation of "doc, how much time do I have?"

Journal of clinical oncology, 2003-05, Vol.21 (9 Suppl), p.8s-11

2003

Volltextzugriff (PDF)

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4135-TPS4135

2018

Volltextzugriff (PDF)

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.91-91

2019

Volltextzugriff (PDF)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS11618-TPS11618

2016

Volltextzugriff (PDF)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS465-TPS465

2016

Volltextzugriff (PDF)

A double‐blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy

Cancer, 1996-07, Vol.78 (1), p.144-151

1996

Volltextzugriff (PDF)

Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B144-B144

2015

Volltextzugriff (PDF)

Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study

Journal of neuro-oncology, 1997-03, Vol.32 (1), p.45-55

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative

Improvement in Oncology Practice Performance Through Voluntary Participation in the Quality Oncology Practice Initiative

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Measuring Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice Initiative

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

Development and future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

Evolution and elements of the quality oncology practice initiative measure set

Caring for patients at the end of life

A revisitation of "doc, how much time do I have?"

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

A double‐blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy

Abstract B144: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study

Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study

Suchergebnisse filtern